Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is increasingly understood as a heterogeneous biological syndrome rather than the nonspecific residue of an acute respiratory illness. Among the mechanisms under investigation, reactivation of persistent human viruses has emerged as a particularly intriguing possibility. Epstein\u2013Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus, human herpesviruses 6 and 7, and anelloviruses can persist within healthy individuals under continuous immune surveillance. SARS-CoV-2 infection can profoundly perturb that surveillance system. The resulting reactivation of latent or persistent viruses may, in some individuals, generate a second wave of antigenic stimulation, inflammatory signaling, endothelial dysfunction, metabolic disturbance, autonomic abnormalities and, potentially, autoimmunity.<\/p>\n\n\n\n
Recent longitudinal multi-omic research has substantially strengthened this hypothesis. In a large cohort studied with viral transcriptomics, host transcriptomics, immune profiling, proteomics and metabolomics, investigators found temporally distinct reactivation of herpesviruses and anelloviruses during and after acute COVID-19. Persistent viral activity during convalescence was associated with some measures of long-COVID illness.\u00b9 Nevertheless, association is not causation. Viral reactivation may be a consequence of severe illness or immune dysfunction rather than its cause. The critical unanswered question is whether eliminating a reactivated virus improves the clinical phenotype in which it is detected.<\/p>\n\n\n\n
The emerging picture is therefore neither that “EBV causes long COVID” nor that viral reactivation is incidental. Rather, SARS-CoV-2 may disturb the equilibrium between the human host and its persistent virome, creating a subset of patients in whom secondary viral activity becomes an amplifier\u2014or potentially a driver\u2014of chronic disease.<\/p>\n\n\n\n
The conventional picture of viral infection is deceptively simple.<\/p>\n\n\n\n
A virus enters the body, replicates, produces symptoms, encounters the immune system, and is eliminated. Recovery then represents the restoration of physiologic equilibrium.<\/p>\n\n\n\n
That model works reasonably well for many acute respiratory infections.<\/p>\n\n\n\n
It is less satisfactory for long COVID.<\/p>\n\n\n\n
Months after SARS-CoV-2 infection, some patients continue to experience fatigue, post-exertional malaise, cognitive dysfunction, neuropathic symptoms, dyspnea, palpitations, gastrointestinal disturbance, sleep abnormalities and autonomic dysfunction. The syndrome can follow severe COVID-19, but it can also follow an apparently minor infection. Contemporary reviews now recognize several interacting mechanisms, including persistent SARS-CoV-2 antigen, immune dysregulation, autoimmunity, endothelial dysfunction, metabolic abnormalities, autonomic dysfunction, microbiome disturbance and reactivation of latent viruses.\u00b2,\u00b3<\/p>\n\n\n\n
The viral-reactivation hypothesis introduces an important conceptual change.<\/p>\n\n\n\n
Perhaps the problem is not simply that SARS-CoV-2 remains.<\/p>\n\n\n\n
Perhaps SARS-CoV-2 changes the ecological conditions under which other viruses live inside us<\/strong>.<\/p>\n\n\n\n The human body is already host to a remarkable collection of persistent viruses. EBV, CMV, HSV and other herpesviruses can remain for decades, usually held in check by immune surveillance. Anelloviruses are extraordinarily common and can persist without producing recognizable disease.<\/p>\n\n\n\n SARS-CoV-2 may disturb this equilibrium.<\/p>\n\n\n\n The result could be a form of postviral virome dysregulation<\/strong> in which the original infection creates conditions allowing previously suppressed viruses to become transcriptionally or replicatively active.<\/p>\n\n\n\n The implications are considerable. If reactivation is merely a marker of immune dysfunction, antiviral therapy may accomplish little. If reactivation is a driver of disease, however, it creates an entirely different therapeutic target.<\/p>\n\n\n\n Humans are not sterile ecosystems.<\/p>\n\n\n\n The human virome includes viruses that establish chronic or latent relationships with their hosts. Some remain almost completely silent; others periodically express viral genes without producing clinically apparent infection.<\/p>\n\n\n\n Herpesviruses are the classic examples.<\/p>\n\n\n\n EBV infects most humans and establishes lifelong latency principally in B lymphocytes.\u00b3,\u2074<\/p>\n\n\n\n The virus passes through several biologic states, including:<\/p>\n\n\n\n The latent-to-lytic transition is controlled by a complex viral transcriptional program. The immediate-early proteins BZLF1 and BRLF1 initiate a cascade that activates viral DNA replication and subsequent structural-gene expression.\u2074,\u2075<\/p>\n\n\n\n CMV establishes persistence primarily within cells of the myeloid lineage and can influence endothelial, epithelial and immune-cell biology.<\/p>\n\n\n\n Its reactivation is particularly associated with severe physiologic stress and impaired cellular immune surveillance.<\/p>\n\n\n\n HSV-1 and HSV-2 establish latency within sensory neurons.<\/p>\n\n\n\n That anatomical location makes HSV fundamentally different from EBV and CMV. Reactivation can involve viral transcription and axonal transport without necessarily producing substantial circulating viremia.<\/p>\n\n\n\n These viruses establish persistent infections and can reactivate during immune perturbation.<\/p>\n\n\n\n Anelloviruses are among the most prevalent persistent viruses in humans. Their clinical significance remains uncertain, but their abundance makes them potentially important indicators of the state of the host immune system.<\/p>\n\n\n\n The important point is that viral persistence is normal biology<\/strong>.<\/p>\n\n\n\n The question is what happens when SARS-CoV-2 disrupts the equilibrium.<\/p>\n\n\n\n Latent viruses do not ordinarily require eradication because the immune system keeps them under control.<\/p>\n\n\n\n That surveillance depends on:<\/p>\n\n\n\n SARS-CoV-2 can perturb almost every component of this network.<\/p>\n\n\n\n Longitudinal immunologic studies have demonstrated persistent abnormalities in T-cell populations, inflammatory signaling and adaptive immunity after SARS-CoV-2 infection.\u2076<\/p>\n\n\n\n The resulting condition is not necessarily conventional immunodeficiency.<\/p>\n\n\n\n It may instead be immune misregulation<\/strong>.<\/p>\n\n\n\n The immune system may simultaneously be:<\/p>\n\n\n\n This creates a paradox:<\/p>\n\n\n\n an immune system that is highly activated can nevertheless be less effective at controlling latent viruses.<\/strong><\/p>\n\n\n\n That paradox is characteristic of several chronic viral and inflammatory diseases.<\/p>\n\n\n\n Of all latent viruses, EBV has generated the strongest long-COVID literature.<\/p>\n\n\n\n The biological rationale is compelling.<\/p>\n\n\n\n EBV resides within B cells, and SARS-CoV-2 profoundly alters B-cell biology and adaptive immune responses. If immune surveillance becomes dysfunctional, EBV-infected cells may enter a more active transcriptional state.<\/p>\n\n\n\n This does not necessarily mean explosive viral replication.<\/p>\n\n\n\n There may be a spectrum:<\/p>\n\n\n\n latency \u2192 early lytic transcription \u2192 protein expression \u2192 partial replication \u2192 productive replication.<\/strong><\/p>\n\n\n\n Consequently, different laboratory tests detect different stages of the process.<\/p>\n\n\n\n A positive EBV antibody test does not necessarily mean active replication.<\/p>\n\n\n\n An increase in early-antigen antibodies may suggest recent activity.<\/p>\n\n\n\n EBV DNA in blood is stronger evidence.<\/p>\n\n\n\n Viral RNA transcripts are stronger still because they demonstrate viral gene expression.<\/p>\n\n\n\n The distinction is essential when interpreting long-COVID studies.<\/p>\n\n\n\n Several early studies found increased serologic evidence of EBV reactivation among people with persistent symptoms after COVID-19.\u2077\u2013\u2079<\/p>\n\n\n\n A particularly influential investigation associated evidence of EBV reactivation with fatigue and cognitive symptoms after SARS-CoV-2 infection.\u2078<\/p>\n\n\n\n More recent work has strengthened the association.<\/p>\n\n\n\n A 2025 study of patients with persistent fatigue and post-exertional malaise found EBV DNA more frequently among patients with post-COVID symptoms than among recovered controls.\u2079<\/p>\n\n\n\n A 2026 study additionally reported increased interferon-\u03b3 responses to EBV peptides among patients with long-term post-COVID symptoms and examined the relationship between EBV reactivation and circulating blood microaggregates.\u00b9\u2070<\/p>\n\n\n\n These observations are intriguing but must be interpreted cautiously.<\/p>\n\n\n\n An EBV-reactivation signal could mean:<\/p>\n\n\n\n Only prospective intervention can reliably distinguish these possibilities.<\/p>\n\n\n\n The strongest recent evidence comes from a large longitudinal investigation of viral reactivation during and after COVID-19.<\/p>\n\n\n\n Researchers analyzed more than 1,100 hospitalized patients using an unusually broad collection of measurements, including viral RNA sequencing, host transcriptomics, immune-cell profiling, cytokines, proteomics and metabolomics.\u00b9<\/p>\n\n\n\n This matters because earlier studies frequently relied upon indirect markers such as antibody titers.<\/p>\n\n\n\n The investigators instead asked:<\/p>\n\n\n\n Which viruses are transcriptionally active, when do they become active, where are they detected, and what happens to the host simultaneously?<\/strong><\/p>\n\n\n\n They found evidence of reactivation involving multiple viral families, including:<\/p>\n\n\n\n Different viruses followed different temporal trajectories.<\/p>\n\n\n\n EBV tended to appear earlier.<\/p>\n\n\n\n CMV and HSV-1 demonstrated different kinetics.<\/p>\n\n\n\n Anelloviridae showed another pattern, including persistent activity into convalescence.<\/p>\n\n\n\n This finding undermines the simplistic idea that “viral reactivation” represents one biological event.<\/p>\n\n\n\n It is better understood as a dynamic alteration of the host’s viral ecosystem<\/strong>.<\/p>\n\n\n\n The most interesting implication of the multi-omic findings may be conceptual rather than diagnostic.<\/p>\n\n\n\n Suppose the human virome normally exists in equilibrium:<\/p>\n\n\n\n latent viruses \u2194 immune surveillance<\/strong><\/p>\n\n\n\n SARS-CoV-2 introduces a major perturbation:<\/p>\n\n\n\n SARS-CoV-2 \u2192 immune dysregulation \u2192 loss of viral equilibrium \u2192 secondary viral activity<\/strong><\/p>\n\n\n\n The secondary viruses then produce additional antigens and stimulate the immune system.<\/p>\n\n\n\n The system becomes:<\/p>\n\n\n\n SARS-CoV-2 \u2192 immune disruption \u2192 viral reactivation \u2192 inflammation \u2192 further immune disruption.<\/strong><\/p>\n\n\n\n This may constitute a positive feedback loop.<\/p>\n\n\n\n The original virus does not necessarily need to remain continuously replicative.<\/p>\n\n\n\n It may only need to initiate an immunologic state that permits another virus to become active.<\/p>\n\n\n\n CMV deserves special consideration because of its relationship to immune and endothelial physiology.<\/p>\n\n\n\n CMV can affect:<\/p>\n\n\n\n The 2026 longitudinal study found CMV activity with distinct kinetics from EBV.\u00b9<\/p>\n\n\n\n This raises the possibility that CMV reactivation could contribute to a different long-COVID phenotype from EBV.<\/p>\n\n\n\n One hypothetical pathway is:<\/p>\n\n\n\n SARS-CoV-2 endothelial injury<\/strong><\/p>\n\n\n\n plus<\/p>\n\n\n\n CMV reactivation<\/strong><\/p>\n\n\n\n leading to<\/p>\n\n\n\n persistent endothelial activation<\/strong><\/p>\n\n\n\n followed by:<\/p>\n\n\n\n The hypothesis is attractive because vascular dysfunction is increasingly recognized as one component of long COVID.\u00b2,\u00b3<\/p>\n\n\n\n But it remains a hypothesis.<\/p>\n\n\n\n HSV illustrates one of the fundamental limitations of blood testing.<\/p>\n\n\n\n HSV establishes latency inside sensory neurons.<\/p>\n\n\n\n If reactivation occurs within a ganglion or neural tissue, there may be little or no detectable virus in peripheral blood.<\/p>\n\n\n\n A patient could therefore theoretically have:<\/p>\n\n\n\n neural HSV reactivation \u2192 local inflammatory signaling \u2192 neuropathic or autonomic dysfunction<\/strong><\/p>\n\n\n\n without:<\/p>\n\n\n\n detectable blood viremia.<\/strong><\/p>\n\n\n\n This raises an important methodological principle:<\/p>\n\n\n\n A negative blood test does not necessarily exclude tissue-specific viral reactivation.<\/strong><\/p>\n<\/blockquote>\n\n\n\n Future research will therefore need increasingly sophisticated approaches to determine whether particular tissues contain transcriptionally active virus.<\/p>\n\n\n\n The findings concerning Anelloviridae are particularly provocative.<\/p>\n\n\n\n Anelloviruses are widespread and persistent. Their presence is not, by itself, evidence of disease.<\/p>\n\n\n\n Yet persistent Anelloviridae transcription during convalescence was associated in the 2026 study with measures of physical impairment and fatigue.\u00b9<\/p>\n\n\n\n There are at least three possible interpretations.<\/p>\n\n\n\n The viruses themselves may contribute to chronic disease.<\/p>\n\n\n\n Anellovirus activity may reflect inadequate immune surveillance.<\/p>\n\n\n\n Changes in anellovirus activity may indicate that the entire virome has become destabilized.<\/p>\n\n\n\n The third possibility is particularly interesting.<\/p>\n\n\n\n Anelloviruses could eventually become biomarkers of host immune state<\/strong>, even if they are not themselves pathogenic.<\/p>\n\n\n\n A reactivated virus does not necessarily need to destroy tissue directly.<\/p>\n\n\n\n It may instead activate the host immune system.<\/p>\n\n\n\n The 2026 study found associations between viral reactivation and changes in:<\/p>\n\n\n\n This suggests that secondary viral activity may function as an immune amplifier<\/strong>.<\/p>\n\n\n\n The mechanism might therefore be:<\/p>\n\n\n\n virus \u2192 immune activation \u2192 tissue dysfunction<\/strong><\/p>\n\n\n\n rather than:<\/p>\n\n\n\n virus \u2192 direct cytotoxicity \u2192 tissue destruction.<\/strong><\/p>\n\n\n\n This distinction could explain why conventional imaging may appear relatively normal in some severely symptomatic patients.<\/p>\n\n\n\n Functional disturbances can occur without extensive anatomical destruction.<\/p>\n\n\n\n Viral reactivation can stimulate interferons, chemokines and inflammatory cytokines.<\/p>\n\n\n\n Among the pathways implicated in recent studies are:<\/p>\n\n\n\n A possible sequence is:<\/p>\n\n\n\n viral antigen<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n pattern-recognition receptors<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n interferon signaling<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n chemokine production<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n monocyte and lymphocyte recruitment<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n endothelial activation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n tissue inflammation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n additional release of self-antigens<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n autoimmune activation<\/strong><\/p>\n\n\n\n The result is a system in which viral reactivation can indirectly contribute to pathology even if viral replication itself is modest.<\/p>\n\n\n\n The relationship between viral reactivation and autoimmunity is especially important.<\/p>\n\n\n\n EBV is already implicated in several autoimmune diseases, including multiple sclerosis and systemic lupus erythematosus.\u00b9\u00b9,\u00b9\u00b2<\/p>\n\n\n\n Several mechanisms may explain this relationship.<\/p>\n\n\n\n A viral antigen may resemble a host protein.<\/p>\n\n\n\n EBV directly alters B-cell biology.<\/p>\n\n\n\n Inflammation may activate autoreactive lymphocytes that were previously quiescent.<\/p>\n\n\n\n Tissue injury can expose new self-antigens.<\/p>\n\n\n\n Inflammation changes which peptides are presented to T cells.<\/p>\n\n\n\n Thus, viral reactivation could potentially transform an acute antiviral response into a chronic autoimmune state.<\/p>\n\n\n\n The sequence might become:<\/p>\n\n\n\n SARS-CoV-2 \u2192 EBV reactivation \u2192 B-cell activation \u2192 autoreactive clones \u2192 chronic inflammation.<\/strong><\/p>\n\n\n\n This is one reason viral reactivation and autoimmunity should not be considered competing hypotheses.<\/p>\n\n\n\n They may represent successive stages of the same process.<\/p>\n\n\n\n The endothelium may be one of the major convergence points for SARS-CoV-2 and secondary viral infection.<\/p>\n\n\n\n Both SARS-CoV-2 and CMV can affect endothelial biology.<\/p>\n\n\n\n Endothelial activation can produce:<\/p>\n\n\n\n A 2026 Scientific Reports<\/em> study reported an association among EBV reactivation, circulating blood microaggregates and persistent post-COVID symptoms.\u00b9\u2070<\/p>\n\n\n\n The study is provocative, but it should not be interpreted as establishing that so-called “microclots” cause long COVID.<\/p>\n\n\n\n The more cautious conclusion is that viral reactivation and abnormal blood-cell or platelet behavior may coexist within a broader inflammatory vascular state<\/strong>.<\/p>\n\n\n\n That relationship deserves controlled mechanistic investigation.<\/p>\n\n\n\n The nervous system is particularly vulnerable to disturbances in immune and vascular homeostasis.<\/p>\n\n\n\n Several mechanisms may converge:<\/p>\n\n\n\n The blood\u2013brain barrier normally protects neural tissue from circulating immune mediators.<\/p>\n\n\n\n Long COVID has been associated with abnormalities in this barrier and with persistent systemic inflammation.\u00b9\u00b3<\/p>\n\n\n\n If viral reactivation simultaneously increases systemic immune signaling, the nervous system may become particularly susceptible.<\/p>\n\n\n\n This provides a potential biological bridge to:<\/p>\n\n\n\n Viruses are metabolically demanding organisms.<\/p>\n\n\n\n Replication requires:<\/p>\n\n\n\n Viral reactivation can therefore alter cellular metabolism.<\/p>\n\n\n\n At the same time, chronic inflammatory signaling can impair mitochondrial oxidative phosphorylation and increase oxidative stress.<\/p>\n\n\n\n The result could be a vicious cycle:<\/p>\n\n\n\n inflammation \u2192 mitochondrial dysfunction \u2192 metabolic stress \u2192 impaired immune regulation \u2192 greater susceptibility to viral reactivation.<\/strong><\/p>\n\n\n\n This mechanism is particularly relevant to fatigue.<\/p>\n\n\n\n A patient may have apparently adequate resting energy production but inadequate metabolic reserve when physiologic demand increases.<\/p>\n\n\n\n That conceptual framework is consistent with the characteristic phenomenon of post-exertional malaise, although it does not establish that viral reactivation is its cause.<\/p>\n\n\n\n The existence of viral reactivation after SARS-CoV-2 raises a fundamental question:<\/p>\n\n\n\n Why one person and not another?<\/strong><\/p>\n\n\n\n Host genetics almost certainly contributes.<\/p>\n\n\n\n EBV biology provides a useful model.<\/p>\n\n\n\n The ability to control EBV depends upon genetic determinants affecting:<\/p>\n\n\n\n Recent genomic research has identified substantial genetic and immunologic determinants of EBV-associated disease.\u00b9\u2074<\/p>\n\n\n\n HLA variation is particularly important because HLA molecules determine which viral peptides are presented to T cells.<\/p>\n\n\n\n Thus:<\/p>\n\n\n\n host genotype \u2192 antigen presentation \u2192 antiviral surveillance \u2192 latent-virus control<\/strong><\/p>\n\n\n\n could influence susceptibility to post-COVID viral reactivation.<\/p>\n\n\n\n The same principle may apply to CMV, HSV and other persistent viruses.<\/p>\n\n\n\n The viruses themselves are genetically heterogeneous.<\/p>\n\n\n\n EBV strains contain substantial sequence variation, and recent sequencing studies have identified geographic and disease-associated genomic differences.\u00b9\u2075<\/p>\n\n\n\n Viral genomic variation may influence:<\/p>\n\n\n\n For long COVID, this raises another unresolved question:<\/p>\n\n\n\n Could particular viral strains be more likely to reactivate after SARS-CoV-2 infection?<\/strong><\/p>\n\n\n\n There is currently insufficient evidence to answer that question.<\/p>\n\n\n\n But it is increasingly technically feasible.<\/p>\n\n\n\n Future studies could sequence:<\/p>\n\n\n\n This would permit a genuinely mechanistic analysis of host\u2013virus interactions.<\/p>\n\n\n\n An essential distinction must be made between two phenomena.<\/p>\n\n\n\n SARS-CoV-2 itself or its components may remain detectable in tissues after acute infection.<\/p>\n\n\n\n A different persistent virus\u2014such as EBV or CMV\u2014becomes transcriptionally or replicatively active.<\/p>\n\n\n\n The two mechanisms may coexist.<\/p>\n\n\n\n Indeed, they may reinforce one another.<\/p>\n\n\n\n Persistent SARS-CoV-2 antigen could maintain immune activation.<\/p>\n\n\n\n That immune dysregulation could permit EBV or CMV reactivation.<\/p>\n\n\n\n The secondary virus could then add another layer of inflammatory signaling.<\/p>\n\n\n\n Thus some long-COVID patients may experience a multi-virus state<\/strong> rather than a single persistent infection.<\/p>\n\n\n\n The clinical course of viral-reactivation-associated long COVID can be conceptualized in four stages.<\/p>\n\n\n\n The initial infection produces:<\/p>\n\n\n\n Latent viruses may reactivate during this period.<\/p>\n\n\n\n In severe COVID-19, reactivation may simply reflect critical illness.<\/p>\n\n\n\n SARS-CoV-2 declines.<\/p>\n\n\n\n The patient may nevertheless continue to experience:<\/p>\n\n\n\n Some viral-reactivation signals decline.<\/p>\n\n\n\n Others persist.<\/p>\n\n\n\n A subset develops persistent disease.<\/p>\n\n\n\n At this stage, continued viral activity may potentially maintain:<\/p>\n\n\n\n Some patients gradually recover.<\/p>\n\n\n\n Others have a fluctuating course.<\/p>\n\n\n\n The possibility that intermittent viral reactivation contributes to relapses is biologically plausible but presently unproven.<\/p>\n\n\n\n Many patients describe long COVID as a disease that is not static.<\/p>\n\n\n\n Symptoms can improve and then abruptly worsen.<\/p>\n\n\n\n Potential triggers include:<\/p>\n\n\n\n One possible mechanism is transient reactivation of persistent viruses.<\/p>\n\n\n\n Another is autonomic dysregulation.<\/p>\n\n\n\n Another is immune activation unrelated to viral replication.<\/p>\n\n\n\n These mechanisms are not mutually exclusive.<\/p>\n\n\n\n Future longitudinal studies should therefore obtain viral, immune and physiologic measurements during both symptomatic exacerbation and recovery<\/strong>.<\/p>\n\n\n\n That design could answer a crucial question:<\/p>\n\n\n\n Does viral transcription increase before a relapse?<\/p>\n<\/blockquote>\n\n\n\n If the answer is yes, the causal hypothesis becomes substantially stronger.<\/p>\n\n\n\n The field needs to move beyond association.<\/p>\n\n\n\n The strongest evidence would follow five steps.<\/p>\n\n\n\n Viral reactivation must precede the relevant symptoms.<\/p>\n\n\n\n The virus must be demonstrated in a biologically relevant compartment.<\/p>\n\n\n\n The viral activity must alter cellular or physiologic function.<\/p>\n\n\n\n The effect should correspond to a recognizable clinical phenotype.<\/p>\n\n\n\n Suppressing the virus should improve the phenotype.<\/p>\n\n\n\n The fifth criterion is decisive.<\/p>\n\n\n\n If EBV-positive patients with fatigue improve consistently after a well-designed EBV-directed intervention, causality becomes compelling.<\/p>\n\n\n\n If they do not, EBV may be a biomarker rather than a driver.<\/p>\n\n\n\n The biological hypothesis is attractive enough that some clinicians and patients have experimented with antiviral therapy.<\/p>\n\n\n\n That does not constitute evidence of efficacy.<\/p>\n\n\n\n Antivirals such as acyclovir, valacyclovir, ganciclovir and valganciclovir have distinct targets, pharmacology and toxicities.<\/p>\n\n\n\n There is currently insufficient evidence to recommend routine treatment of long COVID on the basis of presumed EBV or CMV reactivation.<\/p>\n\n\n\n The 2026 international clinical guideline continues to emphasize evidence-based diagnosis and individualized management rather than routine antiviral treatment for presumed latent-virus reactivation.\u00b9\u2076<\/p>\n\n\n\n This is an area in which rigorous clinical trials are urgently needed.<\/p>\n\n\n\n Future trials should not enroll all patients with long COVID as though they possess the same disease.<\/p>\n\n\n\n Instead, patients should be stratified biologically.<\/p>\n\n\n\n Possible characteristics:<\/p>\n\n\n\n Possible characteristics:<\/p>\n\n\n\n Possible characteristics:<\/p>\n\n\n\n Possible characteristics:<\/p>\n\n\n\n Such trials could determine whether specific viruses are:<\/p>\n\n\n\n drivers, amplifiers, biomarkers, or innocent bystanders.<\/strong><\/p>\n\n\n\n The next generation of research must move beyond blood.<\/p>\n\n\n\n Blood is convenient but biologically incomplete.<\/p>\n\n\n\n A virus can persist in:<\/p>\n\n\n\n A negative blood PCR does not exclude localized viral activity.<\/p>\n\n\n\n The ideal future study would combine:<\/p>\n\n\n\n The objective is not merely to find a virus.<\/p>\n\n\n\n It is to establish the relationship:<\/p>\n\n\n\n virus \u2192 tissue \u2192 molecular effect \u2192 physiologic consequence \u2192 symptom.<\/strong><\/p>\n\n\n\n The most plausible model is not that viral reactivation explains all long COVID.<\/p>\n\n\n\n Rather, it may interact with several other mechanisms.<\/p>\n\n\n\n Provides continuing antigenic stimulation.<\/p>\n\n\n\n Adds secondary antigenic stimulation.<\/p>\n\n\n\n Produces tissue-directed immune responses.<\/p>\n\n\n\n Impedes microvascular physiology.<\/p>\n\n\n\n Disturbs cardiovascular and gastrointestinal regulation.<\/p>\n\n\n\n Reduces metabolic reserve.<\/p>\n\n\n\n Changes mucosal immunity and systemic signaling.<\/p>\n\n\n\n The resulting network might look like:<\/p>\n\n\n\n SARS-CoV-2<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n immune dysregulation<\/strong><\/p>\n\n\n\n \u2199 \u2193 \u2198<\/p>\n\n\n\n viral persistence<\/strong> \u2014 viral reactivation<\/strong> \u2014 autoimmunity<\/strong><\/p>\n\n\n\n \u2193 \u2193 \u2193<\/p>\n\n\n\n endothelial dysfunction<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n autonomic + metabolic + neurologic dysfunction<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n persistent multisystem disease<\/strong><\/p>\n\n\n\n This model accommodates the extraordinary heterogeneity of long COVID.<\/p>\n\n\n\n It is tempting to say:<\/p>\n\n\n\n “EBV reactivation causes long COVID.”<\/p>\n<\/blockquote>\n\n\n\n The evidence does not justify that statement.<\/p>\n\n\n\n A more defensible conclusion is:<\/p>\n\n\n\n SARS-CoV-2 infection can be associated with reactivation of persistent viruses, and accumulating evidence suggests that persistent or recurrent viral activity may contribute to chronic symptoms in a biologically defined subset of patients.<\/strong><\/p>\n<\/blockquote>\n\n\n\n That distinction matters enormously.<\/p>\n\n\n\n EBV infection is nearly ubiquitous.<\/p>\n\n\n\n Therefore, the mere presence of EBV cannot explain why only some people develop long COVID.<\/p>\n\n\n\n The critical variable may instead be:<\/p>\n\n\n\n what the virus is doing, where it is doing it, when it is doing it, and how the host responds.<\/strong><\/p>\n\n\n\n Taken together, the evidence supports a broader hypothesis.<\/p>\n\n\n\n SARS-CoV-2 may not simply cause a persistent disease of one virus.<\/p>\n\n\n\n It may cause a disturbance of the host\u2013virome relationship<\/strong>.<\/p>\n\n\n\n The normal state:<\/p>\n\n\n\n persistent viruses + immune surveillance = equilibrium<\/strong><\/p>\n\n\n\n After SARS-CoV-2:<\/p>\n\n\n\n SARS-CoV-2 + altered immunity = virome instability<\/strong><\/p>\n\n\n\n The consequences could include:<\/p>\n\n\n\n The clinical syndrome would then represent the cumulative physiologic consequences of this altered ecosystem.<\/p>\n\n\n\n This hypothesis explains why long COVID can look so different from one patient to another.<\/p>\n\n\n\n The viral-reactivation hypothesis has progressed considerably since the earliest observations of EBV antibodies in people with persistent symptoms after COVID-19.<\/p>\n\n\n\n The most important advance has been methodological.<\/p>\n\n\n\n Researchers are increasingly able to distinguish viral presence from viral activity<\/strong>, and viral activity from its consequences.<\/p>\n\n\n\n Recent longitudinal multi-omic work demonstrates that SARS-CoV-2 infection can be accompanied by reactivation of several persistent viruses and that different viruses display distinct temporal trajectories.\u00b9 The association of persistent viral activity during convalescence with measures of long-COVID disease strengthens the possibility that secondary viral activity may participate in chronic pathogenesis.<\/p>\n\n\n\n EBV remains the leading candidate because of its ubiquity, biology and relationship to immune dysregulation. CMV offers a plausible connection to endothelial and immune pathology. HSV provides a potential explanation for tissue-specific neurological phenomena that may not be visible in blood. Anelloviruses raise the possibility that changes in the broader human virome may themselves serve as biomarkers of immune dysfunction.<\/p>\n\n\n\n But the central scientific question remains unresolved.<\/p>\n\n\n\n Does viral reactivation cause long COVID, perpetuate it, amplify it, or simply mark the immune disturbance produced by SARS-CoV-2?<\/strong><\/p>\n\n\n\n The answer will not come from another cross-sectional antibody study.<\/p>\n\n\n\n It will require longitudinal sampling, tissue-specific viral transcriptomics, host genomics, single-cell immunology, functional experiments and, above all, randomized trials in biologically defined patients.<\/p>\n\n\n\n If those studies demonstrate that suppressing a reactivated virus reverses a corresponding clinical phenotype, the consequences will be profound.<\/p>\n\n\n\n Long COVID would no longer be conceptualized solely as a lingering aftermath of SARS-CoV-2.<\/p>\n\n\n\n It would become, in some patients, a secondary postviral disorder of the human virome<\/strong>\u2014a disease in which the initial infection destabilizes a lifelong relationship between host and persistent viruses, allowing one or more normally controlled viral populations to become active participants in chronic disease.<\/p>\n\n\n\n That possibility is now sufficiently supported to warrant intensive investigation, but not yet sufficiently established to justify treating every patient with long COVID for an assumed latent-virus reactivation.<\/p>\n\n\n\n The distinction between those two positions\u2014between biological plausibility and demonstrated causality<\/strong>\u2014is where the next decisive advances in long-COVID research will occur.<\/p>\n\n\n\n Abstract Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is increasingly understood as a heterogeneous biological syndrome rather than the nonspecific residue of an acute respiratory illness. Among the […]<\/p>\n","protected":false},"author":2,"featured_media":15785,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1524,1240,152,214,1523,1525,1521,1522],"tags":[],"class_list":["post-15766","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-anelloviruse","category-cytomegalovirus","category-epstein-barr","category-herpes-simplex","category-human-virome","category-immune-misregulation","category-viral-reactivation","category-virome-dysregulation"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15766"}],"version-history":[{"count":4,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15766\/revisions"}],"predecessor-version":[{"id":15784,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15766\/revisions\/15784"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/15785"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n\n\n\nI. The Human Virome: A Permanent Biological Companion<\/h5>\n\n\n\n
Epstein\u2013Barr virus<\/h5>\n\n\n\n
\n
Cytomegalovirus<\/h5>\n\n\n\n
Herpes simplex virus<\/h5>\n\n\n\n
HHV-6 and HHV-7<\/h5>\n\n\n\n
Anelloviruses<\/h5>\n\n\n\n
\n\n\n\nII. How SARS-CoV-2 Could Permit Reactivation<\/h5>\n\n\n\n
\n
\n
\n\n\n\nIII. EBV: The Most Studied Candidate<\/h5>\n\n\n\n
\n\n\n\nIV. What the Clinical Evidence Shows About EBV<\/h5>\n\n\n\n
\n
\n\n\n\nV. The 2026 Multi-Omic Breakthrough<\/h5>\n\n\n\n
\n
\n\n\n\nVI. A New Concept: Virome Dysregulation<\/h5>\n\n\n\n
\n\n\n\nVII. CMV: A Potential Vascular Amplifier<\/h5>\n\n\n\n
\n
\n
\n\n\n\nVIII. HSV and the Problem of Invisible Tissue Reactivation<\/h5>\n\n\n\n
\n
\n\n\n\nIX. Anelloviruses: Signal or Pathogen?<\/h5>\n\n\n\n
Interpretation 1: Anelloviruses are pathogenic<\/h5>\n\n\n\n
Interpretation 2: They are immunologic biomarkers<\/h5>\n\n\n\n
Interpretation 3: They are ecological indicators<\/h5>\n\n\n\n
\n\n\n\nX. The Host Response May Be More Important Than the Virus<\/h5>\n\n\n\n
\n
\n\n\n\nXI. Cytokines and the Inflammatory Feed-Forward Loop<\/h5>\n\n\n\n
\n
\n\n\n\nXII. Viral Reactivation and Autoimmunity<\/h5>\n\n\n\n
Molecular mimicry<\/h5>\n\n\n\n
B-cell stimulation<\/h5>\n\n\n\n
Bystander activation<\/h5>\n\n\n\n
Epitope spreading<\/h5>\n\n\n\n
Altered antigen presentation<\/h5>\n\n\n\n
\n\n\n\nXIII. Endothelial Dysfunction<\/h5>\n\n\n\n
\n
\n\n\n\nXIV. The Nervous System<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXV. Mitochondrial Physiology<\/h5>\n\n\n\n
\n
\n\n\n\nXVI. Genomics: Why Some People Reactivate Viruses<\/h5>\n\n\n\n
\n
\n\n\n\nXVII. Viral Genomics<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXVIII. Persistent SARS-CoV-2 Versus Reactivated Viruses<\/h5>\n\n\n\n
Persistent SARS-CoV-2<\/h5>\n\n\n\n
Secondary viral reactivation<\/h5>\n\n\n\n
\n\n\n\nXIX. The Clinical Course<\/h5>\n\n\n\n
Stage 1: Acute SARS-CoV-2 infection<\/h5>\n\n\n\n
\n
Stage 2: Early convalescence<\/h5>\n\n\n\n
\n
Stage 3: Established PASC<\/h5>\n\n\n\n
\n
Stage 4: Relapsing or resolving disease<\/h5>\n\n\n\n
\n\n\n\nXX. Why Relapses Are Scientifically Interesting<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXXI. What Would Prove Causality?<\/h5>\n\n\n\n
1. Temporal precedence<\/h5>\n\n\n\n
2. Tissue localization<\/h5>\n\n\n\n
3. Functional effect<\/h5>\n\n\n\n
4. Phenotype specificity<\/h5>\n\n\n\n
5. Therapeutic reversal<\/h5>\n\n\n\n
\n\n\n\nXXII. Why Antiviral Therapy Is Not Yet Established Treatment<\/h5>\n\n\n\n
\n\n\n\nXXIII. A Better Clinical-Trial Strategy<\/h5>\n\n\n\n
EBV-positive phenotype<\/h5>\n\n\n\n
\n
CMV-positive phenotype<\/h5>\n\n\n\n
\n
HSV-positive neurological phenotype<\/h5>\n\n\n\n
\n
Anellovirus-associated phenotype<\/h5>\n\n\n\n
\n
\n\n\n\nXXIV. The Importance of Tissue<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXXV. Viral Reactivation as Part of a Larger Disease Network<\/h5>\n\n\n\n
Persistent SARS-CoV-2<\/h5>\n\n\n\n
Viral reactivation<\/h5>\n\n\n\n
Autoimmunity<\/h5>\n\n\n\n
Endothelial dysfunction<\/h5>\n\n\n\n
Autonomic dysfunction<\/h5>\n\n\n\n
Mitochondrial dysfunction<\/h5>\n\n\n\n
Microbiome disturbance<\/h5>\n\n\n\n
\n\n\n\nXXVI. The Most Important Scientific Caveat<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXXVII. The Emerging Concept of a Post-SARS-CoV-2 Virome Disorder<\/h5>\n\n\n\n
\n
\n\n\n\nXXVIII. Conclusion<\/h5>\n\n\n\n
\n\n\n\nNumbered References<\/h5>\n\n\n\n
\n